Bliss GVS Pharma Limited (BLISSGVS) fundamentals
Bliss GVS Pharma Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as BLISSGVS (ISIN INE416D01022). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Bliss GVS Pharma Limited does
Bliss GVS Pharma Limited is engaged in developing, manufacturing, and marketing pharmaceutical formulations. The Company’s product categories include pharma products, other healthcare products, and therapeutic index. Its pharma products include pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, oral solids, and others. The Company’s other healthcare products include balm, nasal inhaler, solution, soap, roll on, shampoo, powder, spray, and petroleum jelly. Its brands include ANOMEX, ANOMEX DS, CONLAX 5/10, G - ALFENAC 100, GACET 80/125/170/250/500/1G, GMETH - 50/100, GSUNATE - 50/100/200, GVCAM - 7.5/15, GV-SOFT 1/2/3/4 G, LOFNAC - 12.5/25/50/100, MEFINOL, MELANEZ, MENINA - 25/100, TYRIDOL, VIGOTAMIN, COMIT 50, BG - CLIND, VAGID CL, ECOZOLE, GVGYL 500, GYNANFORT, GVGYL N, KLOVINAL, LONART, LONART FORTE, LONART Dispersible, FINMOL, GACET-500, NOVOGLIP-5, GVZOLE, and DOXYCYCLINE.
Valuation and market data
| Last close | ₹720.95 |
|---|---|
| Market capitalisation | ₹7,942 crore |
| Enterprise value | ₹7,932 crore |
| P/E (TTM) | 58.95 |
| Price to book | 6.45 |
| Price to sales (TTM) | 4.64 |
| Book value per share | ₹111.81 |
| Dividend yield | 20.81% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Jul 26 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹774 crore | ₹133 crore | ₹97 crore | 9.17 |
| Mar 2025 | ₹703 crore | ₹94 crore | ₹69 crore | 6.56 |
| Mar 2024 | ₹639 crore | ₹70 crore | ₹51 crore | 4.85 |
| Mar 2023 | ₹649 crore | ₹116 crore | ₹85 crore | 8.23 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 35.0% |
|---|---|
| Foreign institutions (FII) | 8.1% |
| Mutual funds | 0.3% |
| Other domestic institutions | 9.2% |
| Retail and others | 47.5% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.